By Blossom Ukoha
“I’m honored to be announced as the next CEO of the Alzheimer’s Drug Discovery Foundation.
Alzheimer’s is one of the defining health challenges of our time, but we are living in a moment of real progress. The clinical pipeline is expanding, blood-based diagnostics are changing how we detect disease, and advances in AI are helping accelerate the pace of discovery. Together with growing evidence around prevention, there is new momentum in the field and real reason for hope.”
With this statement, Isobel Coleman sets the tone for her new role as Chief Executive Officer of the Alzheimer’s Drug Discovery Foundation, which took effective March 23, 2026. Her appointment comes at a critical moment as Alzheimer’s research enters a phase of accelerated scientific progress.
Coleman brings extensive leadership experience across government, private sector, and nonprofit institutions. Most recently, she served as Deputy Administrator of the U.S. Agency for International Development, where she oversaw more than 15,000 employees and managed a portfolio exceeding 35 billion dollars annually. Her background as a former McKinsey partner and a twice Senate-confirmed diplomat with the rank of Ambassador reflects a career built on navigating complex global systems and delivering measurable impact.
Isobel Coleman is a seasoned policy expert, strategist, and global development leader with decades of experience across public, private, and nonprofit sectors. She has held senior leadership roles that span international diplomacy, economic strategy, and institutional management. At McKinsey, she advised organizations on strategy and transformation, while her diplomatic roles positioned her at the forefront of global policy and international cooperation.
Her tenure at USAID further solidified her reputation as a results-driven leader capable of managing large-scale operations and aligning diverse stakeholders toward shared goals. Throughout her career, Coleman has been recognized for her ability to operate at the intersection of policy, innovation, and development, consistently driving initiatives that deliver both strategic and social impact.
At the Alzheimer’s Drug Discovery Foundation, she is expected to leverage this multidisciplinary expertise to strengthen partnerships, accelerate scientific breakthroughs, and guide the organization through its next phase of growth.
Her appointment signals a strategic step forward for the foundation as it builds on decades of progress and focuses on advancing solutions that can deliver real outcomes for patients and families worldwide.
Comments are closed.